An observational study in Paroxysmal Atrial Fibrillation (PAF), sponsored by Shenyang Northern Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Shenyang Northern Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 377 studies in Atrial Fibrillation with a site in China — 162 open to participants now, 183 under way, 4 of them phase 3. Atrial Fibrillation · China.
Among the 377 studies in Atrial Fibrillation with a site in China, this one is the 111th largest by planned enrollment of the 121 observational ones that give a count, is one of 48 that started in 2026, is one of 121 observational ones, reaches primary completion later than 111 of the 182 other live ones, and was the 374th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →162 of the 377 studies in Atrial Fibrillation with a site in China are open now. Recruiting first, the newest first:
Biosense Webster, Inc. · Sites in China
Ages 18–80
Johnson & Johnson Medical (Shanghai) Ltd. · Sites in China
Ages 18–80
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Peking Union Medical College Hospital · Sites in China
Ages 60+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
377 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 5 · Phase 3 20 · Phase 4 28
First in 2005; this study’s year is marked. 48 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 300 across 1,405 observational studies indexed under Atrial Fibrillation.
Median enrollment 235 across the 256 interventional studies, 500 across the 121 observational. Of the 110 that completed or were terminated, 24 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 377 have an industry lead sponsor. The 10 most frequent:
Shenyang Northern Hospital is the lead sponsor of 42 studies on the registry; 11 are open to participants now.
Shenyang Northern Hospital has 3 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
50 of the studies in Atrial Fibrillation with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT06722196Phase 3Jilin Heart HospitalBiodEgradable Soaked Amiodarone paTch Use for the Prevention of Atrial Fibrillation After Cardiac Surgery | 2027-01-15 |
| NCT06125925The First Affiliated Hospital with Nanjing Medical UniversityCatheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial) | 2026-11 |
| NCT07139314Capital Medical UniversityTiming of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2 | 2026-11-30 |
| NCT07541339Beijing Anzhen HospitalSafety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation | 2026-12-01 |
Add all 50 to your calendar (.ics) → With an account.
Among the 377 studies in Atrial Fibrillation with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This post-marketing, multi-center, prospective, single-arm, observational study will be conducted across 3 clinical sites in China and enroll no more than 50 patients with paroxysmal atrial fibrillation. After clinical site initiation, each study site was permitted to enroll up to 2 roll-in cases to allow operators to familiarize themselves with the Nordica® cryoballoon and standardize procedural techniques. A competitive enrollment method will be adopted to recruit up to 50 patients with paroxysmal atrial fibrillation. The Nordica® cryoballoon will be employed for pulmonary vein isolation during the procedure. A 6-month follow-up assessment is scheduled at the following time points: the index hospitalization period (days 0-3), and post-procedure follow-up time points at 30 days, 3 months, and 6 months.
Cryoballoon ablation has become an initial therapy for patients with paroxysmal atrial fibrillation, owing to its advantages of procedural standardization, high intraoperative comfort, reliable pulmonary vein isolation, and favorable safety profile. The Nordica® balloon features a single-layer design, offering superior compliance compared to double-layer balloons. This facilitates transmural pulmonary vein isolation (PVI) and reduces the likelihood of segmental ablation and adjacent tissue injury. The balloon maintains an internal pressure of 3 psi or 5 psi with high leak resistance, a design that prevents displacement caused by sudden pressure spikes during ablation and minimizes failures in pulmonary vein isolation due to inadequate contact. Furthermore, the compliant design of the Nordica® balloon conforms better to pulmonary vein anatomy, enabling easy occlusion of the pulmonary veins without the need for additional pushing force. It has been approved for pulmonary vein isolation in this patient population. Previous studies have demonstrated the safety and efficacy of the Nordica® cryoballoon in the treatment of paroxysmal atrial fibrillation. Nevertheless, there is still a lack of multi-center, prospective real-world evidence on the long-term effectiveness, safety, procedural efficiency, and health economic value of the Nordica® cryoballoon in routine clinical practice Therefore, we aim to conduct a multi-center, prospective, single-arm, observational real-world study to assess the post-marketing safety, effectiveness, procedural efficiency, and health economic outcomes of the Nordica® cryoballoon for pulmonary vein isolation in patients with paroxysmal atrial fibrillation, with the goal of developing high-quality, evidence-based guidelines to inform its standardized use in clinical practice.
Patients (aged 18-75 years) was documented paroxysmal atrial fibrillation (PAF), eligible for AF catheter ablation, and scheduled to undergo a cryoballoon-based pulmonary vein isolation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Composite endpoint of 30-day postoperative complications
Including any of the following adverse events: 1. Death (including all-cause mortality and cardiovascular death); 2. Stroke/ transient ischemic attack; 3. Pericardial tamponade / Pericardial Effusion (need drainage or surgical removal); 4. major vascular complications / major bleeding events (resulting in death, blood transfusion, prolonged hospitalization, or surgical/interventional treatment); 5) major vascular complications (requires repair, intervention, or blood transfusion); 6) Symptomatic pulmonary vein stenosis (requires intervention/ surgery); 7) atrioesophageal fistula/ esophageal injury; 8)persistent phrenic nerve injury (persisting beyond 7 days following the index procedure); 9)Severe arrhythmia (requires cardioversion/emergency drug treatment)
Time frame: Within 30 days postoperatively
Incidence of freedom from atrial arrhythmia at 6 months postoperatively
Defined as the proportion of subjects free from any documented atrial tachyarrhythmia - including atrial fibrillation (AF), atrial tachycardia (AT), or atrial flutter (AFL) lasting ≥30 seconds - occurring. These episodes must be confirmed by 12-lead electrocardiogram (ECG) and seven-day Holter monitoring following a 6-month period post-ablation.
Time frame: At 6 months postoperatively
Acute success rate of pulmonary vein isolation
Defined as the proportion of subjects with confirmed complete isolation of all pulmonary veins.
Time frame: Intraoperative
The extended major safety endpoints, minor adverse events, and other medical device adverse event or procedure-related adverse event
1. Transient phrenic nerve palsy (requiring brief intervention therapy, recovered prior to discharge); 2. Minor vascular access complications (without intervention/ surgery); 3. Minor bleeding (without transfusion, surgical/interventional treatment); 4. Asymptomatic pulmonary vein stenosis (without intervention); 5. Non-serious cardiovascular and pulmonary medical device and/or procedure-related adverse events; 6. medical device related adverse events (e.g., mild vascular irritation related to catheter manipulation; device performance anomaly without serious clinical sequelae)
Time frame: Intraoperative/within 30 days postoperatively/at 6 months postoperatively
Procedure efficiency
Will be described using (mean, median, and distribution): total procedure room time, procedure time, pulmonary vein isolation time, left atrial dwell time, the length of hospital stay (LOS), ablation time, the number of ablation applications, time to isolation (TTI), and fluoroscopy time, fluoroscopy dose.
Time frame: Intraoperative
Health economics
Will be described using (mean and distribution): direct medical costs of subjects (procedure cost, device cost, examination costs, medication costs, hospitalization costs, etc.).
Time frame: From enrollment to the end of treatment at 6 months postoperatively
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jun 2027, 8 months later.
Of 552 non-industry observational studies under Atrial Fibrillation, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 91. This study's planned 8 months is below that.
Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shenyang Northern Hospital